Endocyte (ECYT) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Cuts Price Target on Endocyte (ECYT) as Expected Approval Times are Pushed Back
March 3, 2016 7:53 AM ESTWedbush maintained an Outperform rating on Endocyte (NASDAQ: ECYT), and cut the price target to $8.00 (from $12.00), following the company's 4Q. Dose-escalation continues in the Ph 1 studies of EC1456 and EC1169 as MTD has not yet been reached. Once MTD is reached the EC1456 study will enroll up to 40 second-line folate-receptor positive NSCLC... More
